Catalyst
Slingshot members are tracking this event:
FDA Approves CytRx's (CYTR) Plan to Submit a Rolling New Drug Application (NDA) for Aldoxorubicin in Soft Tissue Sarcoma (STS)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CYTR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 19, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Rolling New Drug Application, Nda, Aldoxorubicin, Soft Tissue Sarcoma
